This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.
The objective of the Corrona Psoriasis Registry is to create a national database of patients with psoriasis. Data collected will be used to study the disease and to evaluate the effectiveness and safety of medications approved for the treatment of psoriasis.
The purpose of this study is to evaluate the impact of a Family Healthcare Advocate in management of Type 2 Diabetes and Hypertension among SIU Medicine Endocrinology patients residing in Springfield, IL zip codes 62702 and 62703.
I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.
ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.
Lauriet: The purpose of this study is to compare the effects, good or bad, of MTAU9937A versus placebo on patients with moderate AD. In this study, you will get either MTAU9937A or placebo. MTAU9937A is an experimental drug, which means health authorities such as the Food and Drug Administration (FDA) have not approved it for the treatment of moderate AD or other conditions. MTAU9937A is in early development and has been previously studied in healthy subjects and people with milder forms of Alzheimer’s disease.